A Pilot Study on the Association between SLCO1B1 rs4363657 Polymorphism and Muscle Adverse Events in Adults with Newly Diagnosed Dyslipidaemia who were Prescribed a Statin: The Malaysian Primary Health Care Cohort

Event Abstract Back to Event A Pilot Study on the Association between SLCO1B1 rs4363657 Polymorphism and Muscle Adverse Events in Adults with Newly Diagnosed Dyslipidaemia who were Prescribed a Statin: The Malaysian Primary Health Care Cohort Meor Fairuz Rizal Meor Anuar Shuhaili1, Boon How Chew2, Intan Nureslyna Samsudin1, Hejar Abdul Rahman3, Johnson Stanslas4, Shariful Hasan4, Zalinah Ahmad1 and Subashini C. Thambiah1* 1 Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Malaysia 2 Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Department of Family Medicine, Malaysia 3 Department of Community Health, Faculty of Medicine and Health Sciences, Putra Malaysia University, Malaysia 4 Department of Medicine, Faculty of Medicine and Health Sciences, University Putra Malaysia, Malaysia Background Statin, the first-line treatment for dyslipidaemia, may have suboptimal adherence due to its associated muscle adverse events. This data however, remains limited, due to under-reporting, mis/underdiagnoses or statin-associated muscle adverse events are generally rare. The aim of this study is to determine the association of serum creatine kinase (CK) and rs4363657 polymorphism of SLCO1B1 gene with statin-associated muscle adverse events among dyslipidaemia subjects. Methods This was a prospective cohort study at government health clinics involving newly diagnosed adults with dyslipidaemia. Muscle adverse events were recorded based on the patient’s complaint after a month on statin (lovastatin or simvastatin). Biochemical analyses including CK, fasting lipid profile, apo A1, apo B were taken at baseline and follow-up. Genetic profiling was performed for rs4363657 polymorphism of SLCO1B1 gene. Results A total of 118 subjects participated. Majority were Malay (72%) males (61%) with a mean age of 49 ± 12.2 years old and prescribed lovastatin (61.9%). There was a significant association between types of statin and muscle adverse events (p = 0.0327); frequency of muscle adverse events was higher with lovastatin (15.2%). No significant association noted between CK and muscle adverse events (p = 0.5637). The rs4363657 polymorphism of SLCO1B1 gene was significantly associated with muscle adverse events (p < 0.0001). The frequency of muscle adverse events was highest in CC genotype (100%); TC and TT (wild type) genotypes were 42.31% and 3.57%, respectively. Subjects with TC and CC genotypes were 26.24 and 357.96 times more likely to exhibit muscle adverse events compared to subjects with normal SLCO1B1 gene, respectively (p < 0.0001). Conclusion Statin-associated muscle adverse events were significantly higher in subjects on lovastatin compared to simvastatin. rs4363657 polymorphism of SLCO1B1 gene was a significant risk factor for statin-associated muscle adverse events in this study. Keywords: Dyslipidemia, statin, muscle adverse events, SLCO1B1, rs4363657, Creatine Kinase, Simvastatin, Lovastatin Conference: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”, Putrajaya, Malaysia, 3 Dec - 5 Feb, 2019. Presentation Type: Poster Presentation Topic: Metabolic diseases Citation: Meor Anuar Shuhaili M, Chew B, Samsudin I, Abdul Rahman H, Stanslas J, Hasan S, Ahmad Z and C. Thambiah S (2019). A Pilot Study on the Association between SLCO1B1 rs4363657 Polymorphism and Muscle Adverse Events in Adults with Newly Diagnosed Dyslipidaemia who were Prescribed a Statin: The Malaysian Primary Health Care Cohort. Front. Pharmacol. Conference Abstract: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”. doi: 10.3389/conf.fphar.2018.63.00003 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 11 Oct 2018; Published Online: 17 Jan 2019. * Correspondence: Dr. Subashini C. Thambiah, Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor Daruh Ehsan, Selangor, 43400, Malaysia, subashini@upm.edu.my Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Meor Fairuz Rizal Meor Anuar Shuhaili Boon How Chew Intan Nureslyna Samsudin Hejar Abdul Rahman Johnson Stanslas Shariful Hasan Zalinah Ahmad Subashini C. Thambiah Google Meor Fairuz Rizal Meor Anuar Shuhaili Boon How Chew Intan Nureslyna Samsudin Hejar Abdul Rahman Johnson Stanslas Shariful Hasan Zalinah Ahmad Subashini C. Thambiah Google Scholar Meor Fairuz Rizal Meor Anuar Shuhaili Boon How Chew Intan Nureslyna Samsudin Hejar Abdul Rahman Johnson Stanslas Shariful Hasan Zalinah Ahmad Subashini C. Thambiah PubMed Meor Fairuz Rizal Meor Anuar Shuhaili Boon How Chew Intan Nureslyna Samsudin Hejar Abdul Rahman Johnson Stanslas Shariful Hasan Zalinah Ahmad Subashini C. Thambiah Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.